DS1-H2-1

DS1-H2-1 (Double Spear-I) is a genetically engineered, attenuated West Nile virus (WNV) oncolytic immunotherapy developed by AncoCare Pharmatech. It is designed to selectively infect and lyse tumor cells, particularly neurotropic cancers, while expressing the human T-cell co-stimulatory ligand CD86. This dual mechanism of action combines direct oncolytic tumor destruction with active immunotherapy, where the expressed CD86 co-stimulates T cells in the tumor microenvironment to generate a robust and durable systemic anti-tumor immune response. DS1-H2-1 is being evaluated in clinical trials for the treatment of neuroblastoma, glioblastoma, and other solid tumors.

Other names

Double Spear-I双矛1-H2-1双矛I型溶瘤病毒